BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19291294)

  • 1. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J; Veyrune JL; De Vos J; Klein B
    BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.
    Bossen C; Cachero TG; Tardivel A; Ingold K; Willen L; Dobles M; Scott ML; Maquelin A; Belnoue E; Siegrist CA; Chevrier S; Acha-Orbea H; Leung H; Mackay F; Tschopp J; Schneider P
    Blood; 2008 Feb; 111(3):1004-12. PubMed ID: 17942754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
    Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
    Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.
    Rickert RC; Jellusova J; Miletic AV
    Immunol Rev; 2011 Nov; 244(1):115-33. PubMed ID: 22017435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
    Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
    Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced BAFF-R and increased TACI expression in common variable immunodeficiency.
    Barbosa RR; Silva SL; Silva SP; Melo AC; Pereira-Santos MC; Barata JT; Hammarström L; Cascalho M; Sousa AE
    J Clin Immunol; 2014 Jul; 34(5):573-83. PubMed ID: 24809296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties.
    Schuepbach-Mallepell S; Das D; Willen L; Vigolo M; Tardivel A; Lebon L; Kowalczyk-Quintas C; Nys J; Smulski C; Zheng TS; Maskos K; Lammens A; Jiang X; Hess H; Tan SL; Schneider P
    J Biol Chem; 2015 Jun; 290(26):16330-42. PubMed ID: 25953898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis.
    Pelekanou V; Notas G; Kampa M; Tsentelierou E; Stathopoulos EN; Tsapis A; Castanas E
    PLoS One; 2013; 8(12):e83250. PubMed ID: 24376672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target for triple-negative breast cancer.
    Abo-Elfadl MT; Gamal-Eldeen AM; Ismail MF; Shahin NN
    Cytokine; 2020 Jan; 125():154790. PubMed ID: 31400636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
    Jasek M; Wagner M; Sobczynski M; Wolowiec D; Kuliczkowski K; Woszczyk D; Kielbinski M; Kusnierczyk P; Frydecka I; Karabon L
    Tissue Antigens; 2015 Oct; 86(4):279-84. PubMed ID: 26268376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
    Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
    Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
    Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
    Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL.
    Kanswal S; Katsenelson N; Selvapandiyan A; Bram RJ; Akkoyunlu M
    J Immunol; 2008 Jul; 181(2):976-90. PubMed ID: 18606649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
    Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
    Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACI regulates IgA production by APRIL in collaboration with HSPG.
    Sakurai D; Hase H; Kanno Y; Kojima H; Okumura K; Kobata T
    Blood; 2007 Apr; 109(7):2961-7. PubMed ID: 17119122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAFF, APRIL and their receptors: structure, function and signaling.
    Bossen C; Schneider P
    Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of proteoglycans as the APRIL-specific binding partners.
    Ingold K; Zumsteg A; Tardivel A; Huard B; Steiner QG; Cachero TG; Qiang F; Gorelik L; Kalled SL; Acha-Orbea H; Rennert PD; Tschopp J; Schneider P
    J Exp Med; 2005 May; 201(9):1375-83. PubMed ID: 15851487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells.
    Nys J; Smulski CR; Tardivel A; Willen L; Kowalczyk C; Donzé O; Huard B; Hess H; Schneider P
    PLoS One; 2013; 8(4):e61350. PubMed ID: 23620746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
    Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
    Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.